Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer
Volker Möbus
Breast cancer research and treatment, 2004
View PDFchevron_right
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
Herbert Fritsche
Breast Cancer Res, 2005
View PDFchevron_right
Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2-Negative Breast Cancer?
Francisco Esteva
The Oncologist, 2008
View PDFchevron_right
Circulating Her-2/Neu Extracellular Domain in Breast Cancer Patients-Correlation with Prognosis and Clinicopathological Parameters Including Steroid Receptor, Her-2/Neu Receptor Coexpression
Gordana Horvatić-herceg
Pathology & Oncology Research, 2014
View PDFchevron_right
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy
christos valavanis
Anticancer research
View PDFchevron_right
0055 Analysis of HER-2/neu extracellular domain in serum from breast cancer patients: Correlation with clinicopathologic parameters and prognostic significance
Sasa Kralik
The Breast, 2009
View PDFchevron_right
Kinetics of serum HER2/neu changes in patients with HER2-positive primary breast cancer after initiation of primary chemotherapy
angelin kristin
Cancer, 2007
View PDFchevron_right
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Anthony Sevrin
Breast Cancer Research and Treatment, 2016
View PDFchevron_right
Her2/neu and EGFR Tyrosine Kinase Activation Predict the Efficacy of Trastuzumab-based Therapy in Patients with Metastatic Breast Cancer.
Ruth Müller
International Journal of Cancer, 2006
View PDFchevron_right
Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients
Yutaka Amemiya
Anticancer Research
View PDFchevron_right
Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma
DR KAFIL AKHTAR
2021
View PDFchevron_right
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Antonio Rulli
Annals of Oncology, 2008
View PDFchevron_right
Serum Level of HER2 Extracellular Domain in Iranian Patients with Breast Cancer: A Follow-up Study
Mehrnoosh Doroudchi
2005
View PDFchevron_right
Clinical significance of the quantitative assessment of the cytosolic concentration of HER2/neu protein in breast cancer by immunoenzymatic assay (ELISA
Ma Her
Journal of Cancer Research and Clinical Oncology, 2005
View PDFchevron_right
Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer
SLB Jonna Madsen
Clinical Chemistry and Laboratory Medicine, 2013
View PDFchevron_right
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
Shinji Ohno, Norikazu Masuda, Kenjiro Aogi
BMC Cancer, 2010
View PDFchevron_right
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?
Dirk Bernhardt
Biomarkers in cancer, 2013
View PDFchevron_right
Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma / Islam Barkatullah ... [et al.]
DR KAFIL AKHTAR
2021
View PDFchevron_right
Evaluation of HER-2/neu in Serum and Tissue of Primary and Metastatic Breast Cancer Patients using an Automated Enzyme Immunoassay
Antonio Perasole
The International Journal of Biological Markers, 2001
View PDFchevron_right
Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines
Dr. Ahmed Ghdhban Al-Ziaydi
Termedia Publishing House Ltd., 2024
View PDFchevron_right
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
Paul Delree
European Journal of Cancer, 2007
View PDFchevron_right
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
T. Kroll, Mieczyslaw Gajda
Journal of Cancer Research and Clinical Oncology, 2011
View PDFchevron_right
Serum EGFR and serum HER2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
Andrea Rocca
Cancer, 2007
View PDFchevron_right
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
H. Cortés-funes
Clinical cancer research : an official journal of the American Association for Cancer Research, 2000
View PDFchevron_right
Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
Sijia Lu
OncoTargets and Therapy, 2020
View PDFchevron_right
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
Alvaro Moreno-aspitia
Cancer, 2013
View PDFchevron_right
Prognostic value of expression of intracellular and extracellular domains of HER2 in patients with HER2-possitive breast cancer
Andrzej Kulig
Współczesna Onkologia, 2011
View PDFchevron_right
Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma
Rita Passerini
Anticancer research
View PDFchevron_right
Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
Binod Yadav
Asian Pacific Journal of Cancer Prevention, 2022
View PDFchevron_right